	US 12,257,307 B2
	β-lactam-cannabinoid conjugate molecules
Paul Hershberger, Orlando, FL (US)
Assigned to Diverse Biotech, Inc., Miami, FL (US)
Appl. No. 17/622,319
Filed by Diverse Biotech, Inc., Orlando, FL (US)
PCT Filed Jun. 24, 2020, PCT No. PCT/US2020/039354 § 371(c)(1), (2) Date Dec. 23, 2021, PCT Pub. No. WO2020/263975, PCT Pub. Date Dec. 30, 2020.
Claims priority of provisional application 62/960,064, filed on Jan. 12, 2020.
Claims priority of provisional application 62/899,657, filed on Sep. 12, 2019.
Claims priority of provisional application 62/865,687, filed on Jun. 24, 2019.
Prior Publication US 2022/0257778 A1, Aug. 18, 2022
Int. Cl. A61K 47/55 (2017.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); C07D 463/18 (2006.01); C07D 477/14 (2006.01); C07D 499/883 (2006.01); C07D 501/46 (2006.01)

CPC A61K 47/552 (2017.08) [A61K 45/06 (2013.01); A61K 47/545 (2017.08); C07D 463/18 (2013.01); C07D 477/14 (2013.01); C07D 499/883 (2013.01); C07D 501/46 (2013.01)]

18 Claims

1. A conjugate molecule, or a pharmaceutically acceptable salt thereof, comprising a first β-lactam antibiotic component, a first linker, and a cannabinoid component, wherein the first linker is covalently attached to a first hydroxy group of the cannabinoid component, wherein:

(a) the first β-lactam antibiotic component is selected from the group consisting of a first cephem component, a first carbacephem component, a first penem component, and a first carbapenem component covalently attached at its 3 position to the first linker; or

(b) the first β-lactam antibiotic component is a first monobactam component covalently attached at its 2 position to the first linker.